載入中
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
前收盤價
US$2.98
+US$0.09 · +3.11%
盤中時間採用ET。市場資料可能有所延遲。
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
日內區間
目前US$2.98
52週區間
目前US$2.98
盤中時間採用ET。市場資料可能有所延遲。
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
日內區間
目前US$2.98
52週區間
目前US$2.98
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 132.24萬 USD | 223.9萬 USD | 2390.4萬 USD | 6087.6萬 USD |
| 銷貨成本 | 308.16萬 USD | 479.26萬 USD | 374.5萬 USD | 329.2萬 USD | 165.4萬 USD |
| 毛利 | −308.16萬 USD | −347.02萬 USD | −150.6萬 USD | 2061.2萬 USD | 5922.2萬 USD |
| 研究與開發 | 3435.23萬 USD | 3016.48萬 USD | 1651.5萬 USD | 3643.9萬 USD | 5718.4萬 USD |
| 銷售、一般及管理費用 | 1460.1萬 USD | 927.55萬 USD | 2379.9萬 USD | 1638.3萬 USD | 1708.6萬 USD |
| 營業費用 | 4587.18萬 USD | 3944.03萬 USD | 3656.9萬 USD | 4952.99萬 USD | 7261.57萬 USD |
| 利息收入 | 143.2萬 USD | 128.6萬 USD | 58.5萬 USD | 7.11萬 USD | 2.31萬 USD |
| 利息支出 | 24.07萬 USD | 31.84萬 USD | 31.53萬 USD | 30.16萬 USD | 29.45萬 USD |
| 折舊和攤銷 | 308.16萬 USD | 479.26萬 USD | 374.53萬 USD | 329.19萬 USD | 165.36萬 USD |
| 營業利益 | −4895.34萬 USD | −4291.05萬 USD | −3807.5萬 USD | −2891.8萬 USD | −1339.3萬 USD |
| 淨利 | 1327.37萬 USD | −3410.53萬 USD | −4219.4萬 USD | −1874.1萬 USD | −1714.5萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
